Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found that introducing a novel histone deacetylase inhibitor in hormone therapy treatment can overcome resistance to hormonal therapy.
?We always thought that resistance was primarily an inborn or genetic effect,? said Pamela N. Munster, M.D., director of the Early-Phase Clinical Trials Program at the University of California, San Francisco. ?But this is not the case. Tumors have found a way to modify their genes to become resistant. This process is called ?epigenetics,? where genes are turned on and off, but the sequence of DNA is not altered. We have also found that with this kind of breast cancer, we can prevent that resistance with histone deacetylase (HDAC) inhibitors.?
Munster presented the findings at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held November 12-16, 2011 in the Moscone Center West, San Francisco, CA.
Actions within the cell
Munster and her colleagues found that estrogen receptor (ER)-positive breast cancer tumors alter their genes to create more AKT, a protein that spurs actions within the cell to keep it alive ? the opposite of what tamoxifen is designed to do.
In a preclinical study, researchers introduced the HDAC inhibitor PCI-24781(formerly CRA-024781), a broad spectrum phenyl hydroxamic acid-based, orally bioavailable compound, at an early phase of tamoxifen treatment and found that it reverses the tumor?s survival strategy of increasing production of AKT, thus stopping the tumor cells from developing resistance and leading to higher levels of cell death. ?The HDACs regulate the response of AKT to tamoxifen, and together, the effects of HDAC inhibitors and tamoxifen lead to more cell death if introduced with hormonal therapy,? said Munster.
She added that previous attempts to reverse hormone resistance were made later in the course of hormonal therapy treatment, ?and we think that introducing these approaches earlier may be more successful,? Munster noted.
The next step is to take this drug into clinical trials to investigate whether resistance to therapy can be prevented in patients with ER-positive breast cancer. A new look at AKT as a biomarker may help identify patients who are likely to benefit from this type of treatment.
This study was funded by the National Cancer Institute (NCI).
For more information:
– Nilsa Rivera-Del Valle, et al. PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. International Journal of Cell Biology, Volume 2010, Article ID 207420.
– Adimoolam et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. PNAS December 4, 2007 vol. 104 no. 49 19482-19487.
– Carmen A. Banuelos et al. Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781. Clinical Cancer Research November 2007 13; 6816.